Interim Report January – June 2025
During the second quarter, the company has continued to focus on the commercialisation of the three projects Nanoimod, Nanodotax and NOV 202, as well as exploring interest in the company’s listing on First North. So far, these efforts have not yet resulted in any concrete successes.
The quarter has also been characterised by extensive work on finalising the annual report, holding the annual general meeting, and managing the situation where the company’s equity was found to be less than half of the share capital. Following the decision at the first control meeting to continue operations and not initiate liquidation, the company now has eight months before the question of potential liquidation needs to be reconsidered.
Mats Wiking
CEO and CFO